Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
90 hedge funds and large institutions have $98.4M invested in Marinus Pharmaceuticals, Inc in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 30 closing their positions.
200% more call options, than puts
Call options by funds: $6.41M | Put options by funds: $2.13M
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 96 → 90 (-6)
20% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 30
65% less capital invested
Capital invested by funds: $279M → $98.4M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$13.4M |
| 2 |
JG
Jefferies Group
New York
|
+$8.6M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$8.09M |
| 4 |
Goldman Sachs
New York
|
+$7.42M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$5.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$10.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$9.08M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$6.32M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.09M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3M |
MRNS Hedge Fund Activity: Q4 2018 in Review
90 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2018, worth a combined $98.4M — down 65% from $279M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of MRNS and 24 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 28 added.
The largest buyer was Jennison Associates, adding an estimated $13.4M. The largest seller was Credit Suisse, exiting entirely with an estimated $10.3M sold.
- 90 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2018, down from 96 in Q3 2018.
- Funds reported $98.4M of Marinus Pharmaceuticals, Inc stock for Q4 2018, down 65% quarter-over-quarter.
- 24 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2018 and 30 closed out, a net change of -6 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q4 2018 was Jennison Associates, an estimated $13.4M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q4 2018 was Credit Suisse, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2018.